# US 2014/0228391 A1 · Anise Flavored Medication

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0228391 A1
- Document ID: US20140228391A1
- Status: Published application
- Kind: A1
- Application number: 14/179,606
- Filed: 2014-02-13
- Published: 2014-08-14
- Earliest claimed: 2013-02-13
- Assignees: The Procter & Gamble Company
- Applicants: The Procter & Gamble Company
- Inventors: Allyn Michael Kaufmann; James Carl Grimm; Chelsay Lynn Brewster; Thomas Edward Huetter
- Web page: https://patentgrep.com/patent/US20140228391A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- Y10T 436/173845: Amine and quaternary ammonium
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

An anise flavored liquid medication. The liquid medication contains phenylephrine and an anethole analog that is substantially free of aldehyde groups. In one example, the anethole analog can be 1-methoxy-4-n-propylbenzene.

## Claims

### Claim 1

An anise flavored liquid medication comprising:
a. phenylephrine; and
b. an anethole analog that is substantially free of aldehyde groups.

### Claim 2 (depends on 1)

The liquid medication of claim 1 comprising from about 0.01% to about 0.1% phenylephrine.

### Claim 3 (depends on 1)

The liquid medication of claim 1 comprising from about 1 ppm to about 20 ppm anethole analog.

### Claim 4 (depends on 1)

The liquid medication of claim 1 wherein the anethole analog is 1-methoxy-4-n-propylbenzene.

### Claim 5 (depends on 4)

The liquid medication of claim 4 comprising 1 ppm to 10 ppm 1-methoxy-4-n-propylbenzene.

### Claim 6 (depends on 1)

The liquid medication of claim 1 further comprising a pain reliever selected from the group consisting of acetaminophen, ibuprofen, and combinations thereof.

### Claim 7 (depends on 6)

The liquid medication of claim 6 wherein the pain reliever is acetaminophen.

### Claim 8 (depends on 1)

The liquid medication of claim 1 further comprising dextromethorphan.

### Claim 9 (depends on 1)

The liquid medication of claim 1 further comprising doxylamine succinate.

### Claim 10 (depends on 1)

The liquid medication of claim 1 further comprising from about 3% to about 15% ethanol.

### Claim 11 (depends on 1)

The liquid medication of claim 1 wherein the medication is green.

### Claim 12 (depends on 1)

The liquid medication of claim 1 wherein the medication is intended for use at night.

### Claim 13 (depends on 1)

The liquid medication of claim 1 wherein the medication has a pH of about 2 to about 6.

### Claim 14 (depends on 1)

The liquid medication of claim 1 wherein the liquid medication has a mean loss of phenylephrine of less than about 6% within a 95% confidence interval.

### Claim 15

A dose of an anise flavored liquid medication comprising:
a. 650 mg acetaminophen;
b. 20 mg dextromethorphan hydrobromide;
c. 12.5 mg doxylamine succinate;
d. 10 mg phenylephrine hydrochloride; and
e. an anethole analog.

### Claim 16 (depends on 15)

The dose of liquid medication of claim 15 wherein the anethole analog is 1-methoxy-4-n-propylbenzene.

### Claim 17 (depends on 16)

The dose of liquid medication of claim 16 comprising 1 ppm to 10 ppm 1-methoxy-4-n-propylbenzene.

### Claim 18 (depends on 15)

The dose of liquid medication of claim 15 wherein dose has a mean loss of phenylephrine of less than about 5% within a 95% confidence interval.

### Claim 19

A method for determining the rate of a drug active of a liquid medication comprising the steps of:
a. use an Automated Flow Reaction and Incubation Control Apparatus to forcibly degrade the liquid medication by using a temperature ramp with set increments ranging from 80° C. to 140° C. at a pressure of 6-7 bar for 20 minutes;
b. determine the amount of drug active in a sample;
c. determine the rate of drug active degradation.

### Claim 20 (depends on 19)

The method of claim 19 wherein the drug active is phenylephrine.
